Back to Browse Journals » OncoTargets and Therapy » Volume 6

Drugs for solid cancer the productivity crisis prompts a rethink

Authors Rosel D, Brabek J, Vesely P, Fernandes M

Published Date June 2013 Volume 2013:6 Pages 767—777


Received 13 March 2013, Accepted 7 May 2013, Published 26 June 2013

Video abstract presented by Jan Brábek.

Views: 107

Daniel Rösel,1 Jan Brábek,1 Pavel Veselý,2 Michael Fernandes3

1Department of Cell Biology, Charles University in Prague, Prague, Czech Republic; 2Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic; 3Medbase, Chapel Hill, NC, USA

Abstract: Despite remarkable progress in cancer-drug discovery, the delivery of novel, safe, and sustainably effective products to the clinic has stalled. Using Src as a model, we examine key steps in drug development. The preclinical evidence on the relationship between Src and solid cancer is in sharp contrast with the modest anticancer effect noted in conventional clinical trials. Here, we consider Src inhibitors as an example of a promising drug class directed to invasion and metastasis and identify roadblocks in translation. We question the assumption that a drug-induced tumor shrinkage in preclinical and clinical studies predicts a successful outcome. Our analysis indicates that the key areas requiring attention are related, and include preclinical models (in vitro and mouse models), meaningful clinical trial end points, and an appreciation of the role of metastasis in morbidity and mortality. Current regulations do not reflect the natural history of the disease, and may be unrelated to the key complications: local invasion, metastasis, and the development of resistance. Alignment of preclinical and clinical studies and regulations based on mechanistic trial end points and platforms may help in overcoming these roadblocks. Viewed kaleidoscopically, most elements necessary and sufficient for a novel translational paradigm are in place.

Keywords: cancer, paradigms, Src inhibitors, metastasis, translation, drug resistance

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Efficacy of intraarterial chemoinfusion therapy for locally advanced breast cancer patients: a retrospective analysis of 28 cases

Zhang W, Liu R, Wang YY, Qian S, Wang JH, Yan ZP, Zhang HW

OncoTargets and Therapy 2013, 6:761-765

Published Date: 25 June 2013

Potential use of custirsen to treat prostate cancer

Higano CS

OncoTargets and Therapy 2013, 6:785-797

Published Date: 25 June 2013

Apoptosis and G2/M arrest induced by Allium ursinum (ramson) watery extract in an AGS gastric cancer cell line

Xu XY, Song GQ, Yu YQ, Ma HY, Ma L, Jin YN

OncoTargets and Therapy 2013, 6:779-783

Published Date: 25 June 2013

Pattern of sudden death at Ladoke Akintola University of Technology Teaching Hospital, Osogbo, South West Nigeria

Akinwusi PO, Komolafe AO, Olayemi OO, Adeomi AA

Vascular Health and Risk Management 2013, 9:333-339

Published Date: 24 June 2013

One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles

Kim JH, Chung HH, Jeong MS, Song MR, Kang KW, Kim JS

International Journal of Nanomedicine 2013, 8:2247-2257

Published Date: 21 June 2013

Cyclin D1 affects epithelial–mesenchymal transition in epithelial ovarian cancer stem cell-like cells

Jiao J, Huang L, Ye F, Shi MF, Cheng XD, Wang XY, Hu DX, Xie X, Lu WG

OncoTargets and Therapy 2013, 6:667-677

Published Date: 20 June 2013